Pegah Sasanpour - Department of Surgery, School of Medicine, Zaheden University of Medical Sciences, Zahedan, Iran
Marzieh Ghasemi - Department of Obstetrics and Gynecology, Zahedan University of Medical Sciences, Zahedan, Iran
Maryam Nazemian - Department of Obstetrics and Gynecology, Zahedan University of Medical Sciences, Zahedan, Iran
Narjes Noori - Department of Obstetrics and Gynecology, Zahedan University of Medical Sciences, Zahedan, Iran
Hossein Ansari - Department of Epidemiology and Biostatistics, School of Health, Zaheden University of Medical Sciences, Zahedan, Iran

Background: Endometrial cancer is the most prevalent type of genital system cancers. It is needed to assess discrimination power of CEA, CA ۱۵-۳, CA ۱۲۵ tumor markers in endometrial cancer patients and moreover in cases with abnormal uterine bleeding. We examined tumor markers (CA ۱۵-۳, CA ۱۲۵, CEA) in differentiating endometrial cancer and unusual uterine bleeding. Methods: The present case-control study was conducted on ۶۰ women with endometrial cancer and evidence of abnormal uterine bleeding who referred to Ali Ibn Abitaleb Hospital in Zahedan in ۲۰۲۱. The sampling method was easy and accessible and was used to collect observation information, examination, and data form data. For data analysis, SPSS software version ۲۶, statistical graphs and independent t-test were used. Results: The difference in serum levels of CEA marker tumor in patients of case (endometrial cancer patients) and control (abnormal uterine bleeding patients) was statistically significant. Differences in serum levels of CA ۱۵-۳ tumor marker in patients between case group (endometrial cancer patients) and control (patients with abnormal uterine bleeding) and difference in serum levels of CA ۱۲۵ tumor marker in patients between case (endometrial cancer patients) and control groups (bleeding patients) uterine abnormalities were not statistically significant. Conclusion: Serum level of CEA tumor marker has a statistically significant relationship with endometrial cancer patients and abnormal bleeding patients, but serum tumor marker level CA ۱۵-۳ and serum tumor marker CA ۱۲۵ and with endometrial cancer patients and abnormal bleeding patients do not have.

Abnormal uterine bleeding, Endometrial Cancer